Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
IMMX is expected to report earnings to fall 20.83% to -18 cents per share on February 25
Q4'25
Est.
$-0.19
Q3'25
Missed
by $0.08
Q2'25
Missed
by $0.01
Q1'25
Beat
by $0.08
Q4'24
Est.
$-0.25
The last earnings report on December 03 showed earnings per share of -23 cents, missing the estimate of -15 cents. With 1.55M shares outstanding, the current market capitalization sits at 372.56M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. IMMX showed earnings on December 03, 2025. You can read more about the earnings report here.